TCON Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States...

Stats
Today's Volume	65 774.00
Average Volume	238 003
Market Cap	86.00M
EPS	$0 ( 2024-03-05 )
Next earnings date	( $-0.0600 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-17.18
ATR14	$0.0280 (1.48%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-12	Brown Scott B.	Buy	224 800	Employee Stock Option (Right to Buy)
2023-04-20	Brown Scott B.	Buy	3 500	Common Stock
2024-03-12	Theuer Charles	Buy	518 300	Employee Stock Option (Right to Buy)
2023-10-20	Theuer Charles	Buy	3 500	Common Stock
2023-04-20	Theuer Charles	Buy	3 500	Common Stock

INSIDER POWER
80.84
Last 100 transactions
Buy: 3 843 498 \| Sell: 406 947

Volume Correlation

Long: -0.04 (neutral)

Short: -0.77 (moderate negative)

Signal:(49.253) Neutral

TRACON Pharmaceuticals Correlation

10 Most Positive Correlations
BBCP	0.855
DUOT	0.816

10 Most Negative Correlations
BNIXU	-0.898

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

TRACON Pharmaceuticals Correlation - Currency/Commodity

-0.17
( neutral )

-0.15
( neutral )

0.00
( neutral )

0.35
( neutral )

-0.05
( neutral )

TRACON Pharmaceuticals Financials

Annual	2023
Revenue:	$12.05M
Gross Profit:	$12.03M (99.88 %)
EPS:	$-0.110

Q4	2023
Revenue:	$3.05M
Gross Profit:	$3.04M (99.90 %)
EPS:	$0.0109

Q3	2023
Revenue:	$0
Gross Profit:	$-4 000.00 (0.00 %)
EPS:	$0.290

Q2	2023
Revenue:	$9.00M
Gross Profit:	$9.00M (99.97 %)
EPS:	$-0.200

Financial Reports:

No articles found.

TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.